Sep 2026
Abstract B050: ERK1 splicing switch triggers lethal hyperactivation and overcomes KRAS inhibitor resistance in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer death in the United States by 2040. Oncogenic KRAS, present in ∼90% of PDACs, drives tumor growth through MAPK signaling and ERK1/2 activation. While pan-RAS and mutant-selective KRAS inhibitors can produce initial r...
Luisa F. Escobar-Hoyos, Md Siraj Afjalus, Deanne E. Yugawa et al.
· Cancer Research · 0 citations